author-photo

Brooke Hayward

University of North Carolina at Chapel Hill

4

Papers

76

Citations

Citation Trend

Filter By

Papers (4) Sort By

Journal Conference Others

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII

2009 Haemophilia
Show All
- Source
- Cite
- Save
Citations (75)
Xyntha® is effective and safe in previously treated patients with severe haemophilia A: Final results of a pivotal phase III study

2009 Haemophilia
Show All
- Source
- Cite
- Save
Citations (0)
Investigator-Prescribed Prophylaxis of rFIX (BeneFIX®) in Children <6 Years of Age: Efficacy and Safety Outcomes.

2008 Blood
Show All
- Source
- Cite
- Save
Citations (0)
BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.

2008 Blood
Show All
- Source
- Cite
- Save
Citations (1)